SmartPakSmartPak
  • USEF Network The winner of the $100,000 CSI 3* Grand Prix presented by Split Rock Farm, Inc.​ is Kevin Babington with Shorapur! #SRJT15 5/24/2015 4:43:20 PM
  • USEF Network Margie Engle and Royce jump clear with a 40.14 time. #SRJT2015 5/24/2015 4:39:17 PM
  • USEF Network Meagan Nusz and Sri Aladdin jump clear in 43.59 seconds #SRJT2015 5/24/2015 4:37:08 PM
  • USEF Network Kevin Babington and Shorapur have a clear round and a time of 39.25 to take the lead. #SRJT2015 5/24/2015 4:33:56 PM
  • USEF Network Ali Wolff and Brianda finish on eight jumping faults and a time of 44.30 #SRJT2015 5/24/2015 4:31:55 PM
  • USEF Network David Beisel and Call Me Hannes have four jumping faults in 44.32 seconds. #SRJT2015 5/24/2015 4:30:07 PM
  • USEF Network Andres Rodriguez and Darlon Von Groenhove have a clear round with a time of 40.70. #SRJT2015 5/24/2015 4:26:45 PM
  • USEF Network Charlie Jayne and Valeska finishes with four jumping faults in 41.37 seconds. 5/24/2015 4:24:34 PM
  • USEF Network Meagan Nusz and Leoville 2 has a clear jump-off with a time of 46.99. 5/24/2015 4:22:40 PM
  • USEF Network Kaitlin Campbell and Rocky W jump clear in 40.69 seconds #SRJT2015 5/24/2015 4:20:39 PM

News

Luitpold Pharmaceuticals, Inc. Provides Adequan® (polysulfated glycosaminoglycan) Supply Update

RELEASE: June 27, 2013
AUTHOR/ADMINISTRATOR: Luitpold Pharmaceuticals, Inc.

Shirley, NY– Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan® IM, Adequan® IA, and Adequan® Canine provide the following supplyinterruption update:

Luitpold’s NY facility has undergone significant renovations and upgrades to meet enhanced quality standards and address observations made by the U.S. Food and Drug Administration (FDA). These renovations required cessation of manufacturing and affected Luitpold’s ability to release product. This has resulted in shortages in the marketplace. Luitpold has worked in recent months to optimally allocate inventory and manage the limited remaining supply, which has now been depleted.

Luitpold remains committed to resuming its manufacture and release of Adequan® products. We understand how critically important the Adequan® brands are to the health and well-being of the animals receiving treatment. The company’s latest expectations for reestablishing Adequan® supply to themarket is estimated to be first quarter 2014 however, this hinges upon completion of a successfulinspection by the FDA.

The company has established a dedicated webpage on www.adequan.com where concerned parties can register to receive future communications and updates on this matter. You may also contact our Customer Service Department at 1-800-458-0163.

During this supply interruption, we strongly recommend Veterinarians work together with equine and canine owners and caregivers to evaluate and decide upon the safest and most effective alternative treatments.

Adequan® IM and IA are the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses. Adequan® Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

Contact
Allyn Mann, Director
Luitpold Animal Health
Cell Phone: 816-590-5032
Email: amann@adequan.com

News

Competitions